3-O-Acetyl-α-boswellic acid

CAS No. 89913-60-0

3-O-Acetyl-α-boswellic acid( 3-O-Acetyl-alpha-boswellic acid | α-Boswellic acid acetate )

Catalog No. M29074 CAS No. 89913-60-0

3-O-Acetyl-α-boswellic acid has strong anti-inflammatory activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 109 In Stock
5MG 88 In Stock
10MG 148 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    3-O-Acetyl-α-boswellic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    3-O-Acetyl-α-boswellic acid has strong anti-inflammatory activity.
  • Description
    3-O-Acetyl-α-boswellic acid has strong anti-inflammatory activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    3-O-Acetyl-alpha-boswellic acid | α-Boswellic acid acetate
  • Pathway
    GPCR/G Protein
  • Target
    Prostaglandin Receptor
  • Recptor
    Prostaglandin Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    89913-60-0
  • Formula Weight
    498.748
  • Molecular Formula
    C32H50O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (200.51 mM)
  • SMILES
    CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C2C4CC(C)(C)CCC4(C)CCC32C)C1(C)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Dazoxiben

    Dazoxiben is a potent inhibitor of thromboxane (TX) synthase.

  • Travoprost

    Travoprost is used to treat glaucoma and ocular hypertensionis a potent and selective FP prostaglandin receptor agonist.

  • Carboprost trometham...

    Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin F2α and it can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery.Carboprost tromethamine has been accounted for to be 84-96% successful in the treatment of persistent hemorrhage because of uterine atony.